TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 February 26, 2024
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition December 11, 2023
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer December 5, 2023
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years December 4, 2023
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 10, 2023
